Strs Ohio Has $70,271,000 Stake in Amgen Inc. (AMGN)
Strs Ohio lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 0.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 461,857 shares of the medical research company’s stock after selling 2,826 shares during the period. Strs Ohio owned approximately 0.06% of Amgen worth $70,271,000 as of its most recent filing with the SEC.
Several other hedge funds also recently added to or reduced their stakes in AMGN. Investment House LLC increased its stake in shares of Amgen by 0.5% in the second quarter. Investment House LLC now owns 48,686 shares of the medical research company’s stock valued at $7,408,000 after buying an additional 223 shares in the last quarter. Trutina Financial LLC acquired a new stake in shares of Amgen during the second quarter valued at $242,000. Pitcairn Co. increased its stake in shares of Amgen by 55.7% in the second quarter. Pitcairn Co. now owns 8,029 shares of the medical research company’s stock valued at $1,221,000 after buying an additional 2,871 shares in the last quarter. Stoneridge Investment Partners LLC increased its stake in shares of Amgen by 77.3% in the second quarter. Stoneridge Investment Partners LLC now owns 3,717 shares of the medical research company’s stock valued at $566,000 after buying an additional 1,621 shares in the last quarter. Finally, Court Place Advisors LLC increased its stake in shares of Amgen by 14.7% in the second quarter. Court Place Advisors LLC now owns 1,978 shares of the medical research company’s stock valued at $301,000 after buying an additional 253 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.82% during mid-day trading on Friday, reaching $166.81. The company had a trading volume of 3,999,620 shares. Amgen Inc. has a one year low of $138.06 and a one year high of $176.85. The company has a market capitalization of $124.83 billion, a price-to-earnings ratio of 17.07 and a beta of 0.87. The company has a 50 day moving average price of $171.68 and a 200 day moving average price of $161.02.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. Amgen’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.57 EPS. On average, analysts anticipate that Amgen Inc. will post $11.36 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were given a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s payout ratio is 40.90%.
Several analysts recently weighed in on the company. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $188.11 price objective for the company in a research report on Thursday. Jefferies Group restated a “buy” rating on shares of Amgen in a research report on Wednesday. Citigroup Inc. dropped their price objective on Amgen from $175.00 to $172.00 and set a “neutral” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a research report on Wednesday. Finally, Goldman Sachs Group Inc. restated a “buy” rating and set a $206.00 price objective (up from $204.00) on shares of Amgen in a research report on Tuesday, September 27th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $185.06.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.